DBV Technologies | DBVT - Loan Capital


DBV Technologies reported $0 in Loan Capital for its fiscal quarter ending in March of 2025.





Loan Capital Change Date
Acadia Pharmaceuticals USD 0 0 Mar/2025
Alnylam Pharmaceuticals USD 1.04B 13.75M Sep/2025
BioMarin Pharmaceutical USD 596.66M 501K Sep/2025
DBV Technologies USD 0 0 Mar/2025
Halozyme Therapeutics USD 800.07M 709.03M Sep/2025
Incyte USD 35.37M 3.61M Sep/2025
Insmed USD 539.72M 21.23M Sep/2025
Ionis Pharmaceuticals USD 28.78M 596.71M Sep/2025
Neurocrine Biosciences USD 169.5M 500K Mar/2023
PTC Therapeutics USD 1.84B 298.68M Sep/2025
Sarepta Therapeutics USD 1.04B 104.31M Sep/2025
Ultragenyx Pharmaceutical USD 782.75M 11.3M Jun/2025
United Therapeutics USD 100M 100M Jun/2024